TCF7L2 and myeloid sarcoma: Research indicates that TCF7L2 promotes oligodendrocyte maturation by inhibiting autocrine Bone Morphogenetic Protein 4-mediated (BMP4-mediated) signaling (Zhang et al., 2021), suggesting that modulation of this pathway could potentially overcome differentiation arrest in MS lesions.